Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 1889, 1: 571-572.
Article
Google Scholar
Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR: Evidence for a causal role of parathyroid hormone-related protein in pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996, 98: 1544-1549.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999, 103: 197-206.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol. 1997, 98: 665-672. 10.1046/j.1365-2141.1997.2713086.x.
Article
CAS
PubMed
Google Scholar
Shipman CM, Croucher PI, Russell RGR, Helfrich MA, Rogers MJ: The bisphosphonate incadronate (YM 175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998, 58: 5294-5297.
CAS
PubMed
Google Scholar
Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998, 12: 220-229. 10.1038/sj.leu.2400892.
Article
CAS
PubMed
Google Scholar
Busch M, Rave-Frank M, Hille A, Duhmke E: Influence of clodronate on breast cancer cells in vitro. Eur J Med Res. 1998, 3: 427-431.
CAS
PubMed
Google Scholar
Fromigue D, Siwek B, Body JJ: Bisphosphonates inhibit breast cancer cell proliferation. Calcif Tissue Int. 1999, 64: P261-
Google Scholar
Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonene J, Auriola S, Chilton KM, Russell RG: Molecular mechanism of action of bisphosphonates. Bone. 1999, 24: 73S-79S. 10.1016/S8756-3282(99)00070-8.
Article
CAS
PubMed
Google Scholar
Fleisch H: Development of bisphosphonates. Breast Cancer Res. 2002, 4: 30-34. 10.1186/bcr414.
Article
CAS
PubMed
Google Scholar
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001, 296: 235-242.
CAS
PubMed
Google Scholar
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000, 88: 2961-2978. 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.3.CO;2-C.
Article
CAS
PubMed
Google Scholar
Derenne S, Amiot M, Barille S, Bollette M, Robillard N, Berthaud P, Harousseau JL, Bataille R: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 1999, 14: 2048-2056.
Article
CAS
PubMed
Google Scholar
van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996, 98: 698-705.
Article
CAS
PubMed
PubMed Central
Google Scholar
Senaratne SG, Colston KW: Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res. 2002, 4: 18-23. 10.1186/bcr412.
Article
CAS
PubMed
Google Scholar
Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000, 82: 1459-1468.
Article
CAS
PubMed
PubMed Central
Google Scholar
Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrix. Cancer Res. 1997, 57: 3890-3894.
CAS
PubMed
Google Scholar
Selander KS, Mönkkönen J, Karhukorpi EK, Harkonen P, Han-nuniemi R, Vaanenen HK: Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol. 1996, 50: 1127-1138.
CAS
PubMed
Google Scholar
Virtanen SS, Väänänen HK, Härkönen PL, Lakkakorpi PT: Effects of alendronate on adhesion and invasion of breast and prostate cancer cells. Calcif Tissue Int. 2001, 66: S79-
Google Scholar
Yoneda T, Sasaki A, Mundy GR: Osteolytic bone disease in breast cancer. Breast Cancer Res Treat. 2001, 32: 73-84.
Article
Google Scholar
Sasaki A, Boyce BF, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces metastastic human breast cancer burden in nude mice. Cancer Res. 1995, 55: 3551-3557.
CAS
PubMed
Google Scholar
Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y, Matsumura T: Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer. 1998, 77: 279-285. 10.1002/(SICI)1097-0215(19980717)77:2<279::AID-IJC18>3.0.CO;2-6.
Article
CAS
PubMed
Google Scholar
Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiragu T: Actions of bisphosphonates on bone metastases in animal models of breast carcinoma. Cancer Suppl. 2000, 88: 2979-2988. 10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U.
Article
CAS
Google Scholar
Kostenuik PJ, Ori FW, Suyama K, Singh G: Increased growth rate and tumor burden of spontaneously metastastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res. 1993, 53: 5452-5457.
CAS
PubMed
Google Scholar
Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001, 61: 4418-4424.
CAS
PubMed
Google Scholar
Mundy GR, Yoneda T, Hiraga T: Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenviroment. Semin Oncol. 2001, 28(suppl 6): 35-44. 10.1053/sonc.2001.24158.
Article
Google Scholar
Hall DG, Stoico G: Effect of the bisphosphonate Risedronate on bone metastases in rat mammary adenocarcinoma model system. J Bone Miner Res. 1994, 9: 221-230.
Article
CAS
PubMed
Google Scholar
Krempien B, Diel IJ, Jockle-Kretz B, Buchele R, Andre L: The Walker Carcinosarcoma 256 model of bone metastases, Influence of skeletal metabolism on the development of bone metastases. Verh Dtsch Ges Pathol. 1984, 68: 211-216.
Google Scholar
Krempien B, Manegold C: Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP. Cancer. 1993, 72: 91-98.
Article
CAS
PubMed
Google Scholar
Krempien B, Wingen F, Eichmann T, Muller M, Schmahl D: Protective effects of a prophylactic treatment with bisphosphonate 3-amino-1-hydroxypropanel, 1 bisphonic acid on the development of tumor osteopathies in rat: experimental studies with the Walker Carcinosarcoma 256. Oncology. 1998, 45: 41-46. 10.1159/000009922.
Article
Google Scholar
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducting skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996, 335: 1785-1791. 10.1056/NEJM199612123352401.
Article
CAS
PubMed
Google Scholar
van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol. 1993, 11: 491-498.
CAS
PubMed
Google Scholar
Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases – Long term followup of two randomized, placebo-controlled trials. Cancer. 2000, 88: 1082-1090. 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z.
Article
CAS
PubMed
Google Scholar
Kurth AHA, Kim S-Z, Sedlmeyer I, Hovy L, Bauss F: Treatment with ibandronate preserves bone in experimental tumor-induced bone loss. J Bone Joint Surg. 2000, 82-B: 126-130. 10.1302/0301-620X.82B1.9483.
Article
Google Scholar
Green JR: Anti-tumor potential of bisphosphonates. Med Klin. 2000, 95: 23-28.
CAS
Google Scholar
Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998, 339: 357-363. 10.1056/NEJM199808063390601.
Article
CAS
PubMed
Google Scholar
Saarto T, Blomqvist C, Virkkunen P, Elomaa I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001, 19: 10-17.
CAS
PubMed
Google Scholar